oxcarbazepine

Therapeutic Classification: anticonvulsants

Pharmacologic Classification: carbamazepine analogues

BEERS REMS

Partial seizures (as monotherapy or adjunctive therapy).

Unlabeled Use:

Trigeminal neuralgia.

Blocks sodium channels in neural membranes, stabilizing hyperexcitable states, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses.

Therapeutic effects:

Decreased incidence of seizures.

Absorption: Rapidly absorbed after oral administration and rapidly converted to the active 10-hydroxy metabolite (MHD).

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Extensively converted to the active metabolite, MHD, which is then primarily excreted by the kidneys.

Half-Life: Oxcarbazepine: 2 hr; MHD: 9 hr.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	PO	rapid	4.5 hr‡

‡Steady-state levels of MHD are reached after 2–3 days during twice-daily dosing.

Contraindicated in:

Hypersensitivity to oxcarbazepine, carbamazepine, or eslicarbazepine.

Use Cautiously in:

All patients (may ↑ risk of suicidal thoughts/behaviors);
Renal impairment (↓ dose if CCr <30 mL/min);
Severe hepatic impairment;
Rep: Women of reproductive potential;
OB: May be teratogenic (associated with oral clefts and cardiac abnormalities); levels of active metabolites may gradually ↓ during pregnancy, which may ↑ seizure risk; use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children <2 yr (immediate release) or <6 yr (extended release);
Geri: Appears on Beers list. May worsen or cause syndrome of inappropriate antidiuretic hormone (SIADH) secretion in older adults. Use with caution in older adults and closely monitor sodium concentrations when starting therapy or ↑ dose.

Exercise Extreme Caution in:

Patients positive for HLA-B*1502 alleles (unless benefits clearly outweigh the risks) (↑ risk of serious skin reactions).

Derm: acne, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), urticaria

EENT: abnormal vision, diplopia, nystagmus

Endo: SIADH, hypothyroidism

F and E: ↑thirst, hyponatremia

GI: abdominal pain, nausea, vomiting, dyspepsia

Hemat: lymphadenopathy

Neuro: ataxia, dizziness, drowsiness, gait disturbances, headache, tremor, vertigo, cognitive symptoms, SEIZURES, SUICIDAL THOUGHTS

Misc: hypersensitivity reactions

Drug-drug:

May ↑ levels and risk of toxicity of CYP2C19 substrates, including phenytoin, when used at doses greater than 1200 mg/day; may need to ↓ dose of phenytoin.
May ↓ levels and effectiveness of CYP3A4 substrates, including hormonal contraceptives.
Carbamazepine, phenobarbital, phenytoin, and rifampin may ↓ levels and effectiveness; monitor MHD levels during titration period; may need to adjust dose of oxcarbazepine.

Immediate-release tablets and oral suspension can be interchanged at equal doses.
PO (Adults ): Adjunctive therapy (immediate release): 300 mg twice daily; may ↑ by up to 600 mg/day at weekly intervals up to 1200 mg/day (up to 2400 mg/day may be needed); Conversion to monotherapy (immediate release): 300 mg twice daily; may ↑ by 600 mg/day at weekly intervals, while other antiepileptic drugs are tapered over 3–6 wk; dose of oxcarbazepine should be ↑ up to 2400 mg/day over a period of 2–4 wk; Initiation of monotherapy (immediate release): 300 mg twice daily; ↑ by 300 mg/day every 3rd day, up to 1200 mg/day. Maximum maintenance dose should be achieved over 2–4 wk; Adjunctive therapy or monotherapy (extended release): 600 mg once daily for 1 wk; may ↑ by 600 mg/day at weekly intervals up to 1200–2400 mg once daily; Concurrent use of strong CYP3A4 inducer (carbamazepine, phenobarbital, phenytoin, rifampin) (extended release): Consider initiating therapy with 900 mg once daily.
PO (Children 2–16 yr): Adjunctive therapy (immediate release): 4–5 mg/kg twice daily (up to 600 mg/day); ↑ over 2 wk to achieve 900 mg/day in patients 20–29 kg, 1200 mg/day in patients 29.1–39 kg, and 1800 mg/day in patients >39 kg (range 6–51 mg/kg/day). In patients <20 kg, initial dose of 16–20 mg/kg/day may be used not to exceed 60 mg/kg/day. Conversion to monotherapy (immediate release): 8–10 mg/kg/day given twice daily; may ↑ by 10 mg/kg/day at weekly intervals, whereas other antiepileptic drugs are tapered over 3–6 wk; dose of oxcarbazepine should be ↑ up to 600–900 mg/day in patients ≤20 kg, 900–1200 mg/day in patients 25–30 kg, 900–1500 mg/day in patients 35–40 kg, 1200–1500 mg/day in patients 45 kg, 1200–1800 mg/day in patients 50–55 kg, 1200–2100 mg/day in patients 60–65 kg, and 1500–2100 mg/day in patients 70 kg. Maximum maintenance dose should be achieved over 2–4 wk.
PO (Children 6–17 yr): Adjunctive therapy or monotherapy (extended release): 8–10 mg/kg once daily (up to 600 mg/day) for 1 wk; may ↑ by 8–10 mg/kg/day at weekly intervals over 2–3 wk to achieve 900 mg/day in patients 20–29 kg, 1200 mg/day in patients 29.1–39 kg, and 1800 mg/day in patients >39 kg; Concurrent use of strong CYP3A4 inducer (carbamazepine, phenobarbital, phenytoin, rifampin) (extended release): Consider initiating therapy with 12–15 mg/kg (max dose = 900 mg) once daily.

Renal Impairment

PO (Adults ): CCr<30 mL/min (immediate and extended release). Initiate therapy at 300 mg/day and ↑ slowly to achieve desired response.

(Generic available)

Immediate-release tablets: 150 mg; 300 mg; 600 mg
Extended-release tablets: 150 mg; 300 mg; 600 mg
Oral suspension lemon flavor: 300 mg/5 mL

Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression.
Seizures: Assess frequency, location, duration, and characteristics of seizure activity. Hyponatremia may ↑ frequency and severity of seizures. Implement seizure precautions as indicated.
Monitor for CNS changes. May manifest as cognitive symptoms (psychomotor slowing, difficulty with concentration, speech or language problems), somnolence or fatigue, or coordination abnormalities (ataxia, gait disturbances).
Monitor for skin reactions (rash, erythema, urticaria, pruritus, fever, blistering). Patients with HLA-B*1502 alleles are at ↑ risk for SJS and TEN. If skin reactions occur, discontinue oxcarbazepine.
Monitor for signs/symptoms of DRESS (fever, rash, lymphadenopathy, facial swelling), associated with involvement of other organ systems (hepatitis, nephritis, hematologic abnormalities, myocarditis, myositis) during therapy. May resemble an acute viral infection. Eosinophilia is often present. If signs/symptoms of DRESS occur, discontinue oxcarbazepine.

Lab Test Considerations:

Monitor ECG and serum electrolytes before and periodically during therapy. May cause hyponatremia; usually occurs during the 1st 3 mo of therapy. May require dose ↓, fluid restriction, or discontinuation of therapy. Sodium levels return to normal within a few days of discontinuation.

Do not confuse oxcarbazepine with carbamazepine or oxaprozin.
PO: Administer twice daily with or without food.
- Administer extended-release tablets on an empty stomach, >1 hr before or 2 hr after meals. DNC: Swallow extended-release tablets whole; do not crush, break, or chew.
- Shake oral suspension for ≥10 sec. Withdraw dose using oral dosing syringe supplied by manufacturer. May be mixed in a small glass of water just before administration or swallowed directly from syringe. Rinse syringe with warm water and allow to dry. Discard any unused portion after 7 wk of opening the bottle.

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy. Instruct patient to take oxcarbazepine in equally spaced doses as directed. Take missed doses as soon as possible but not just before next dose; do not double dose. Notify health care provider if >1 dose is missed. Medication should be gradually discontinued to prevent seizures.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications. Advise patient not to take alcohol or other CNS depressants, including opioids, concurrently with this medication.
May cause dizziness, drowsiness, or CNS changes. Advise patients to avoid driving or other activities requiring alertness until response to medication is known. Do not resume driving until health care provider gives clearance based on control of seizure disorder.
Advise patient and caregiver to notify health care provider if thoughts about suicide or dying, attempts to commit suicide, new or worse depression, new or worse anxiety, feeling very agitated or restless, panic attacks, trouble sleeping, new or worse irritability, acting aggressive, being angry or violent, acting on dangerous impulses, an extreme ↑ in activity and talking, or other unusual changes in behavior or mood occur.
Instruct patient to notify health care provider of medication regimen before treatment or surgery.
Advise patient to carry identification describing disease and medication regimen at all times.
Rep: Advise women of reproductive potential to use an additional nonhormonal method of contraception during therapy and until next menstrual period. Instruct patient to notify health care provider if pregnancy is planned or suspected. Encourage patients who become pregnant to enroll in the North American Antiepileptic Drug Pregnancy Registry by calling 1-888-233-2334 or visiting www.aedpregnancyregistry.org. Enrollment must be done by patients themselves.

Decreased incidence of seizures.

Oxtellar XR, Trileptal

NDC Code

0078- Novartis Pharmaceuticals Corporation
- 0078-0337- Trileptal
  - 0078-0337-05- 100 TABLET, FILM COATED in 1 BOTTLE (0078-0337-05)

0078- Novartis Pharmaceuticals Corporation
- 0078-0337- Trileptal
  - 0078-0337-06- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0337-06) / 1 TABLET, FILM COATED in 1 BLISTER PACK (0078-0337-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0357- Trileptal
  - 0078-0357-52- 250 mL in 1 BOTTLE (0078-0357-52)

0078- Novartis Pharmaceuticals Corporation
- 0078-0456- Trileptal
  - 0078-0456-05- 100 TABLET, FILM COATED in 1 BOTTLE (0078-0456-05)

0078- Novartis Pharmaceuticals Corporation
- 0078-0456- Trileptal
  - 0078-0456-35- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0456-35) / 1 TABLET, FILM COATED in 1 BLISTER PACK (0078-0456-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0457- Trileptal
  - 0078-0457-05- 100 TABLET, FILM COATED in 1 BOTTLE (0078-0457-05)

0078- Novartis Pharmaceuticals Corporation
- 0078-0457- Trileptal
  - 0078-0457-35- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0457-35) / 1 TABLET, FILM COATED in 1 BLISTER PACK (0078-0457-61)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8447- Oxcarbazepine
  - 0615-8447-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8447-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8448- Oxcarbazepine
  - 0615-8448-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8448-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8567- Oxcarbazepine
  - 0615-8567-39- 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8567-39)

0781- Sandoz Inc
- 0781-6270- Oxcarbazepine
  - 0781-6270-43- 250 mL in 1 BOTTLE (0781-6270-43)

0904- Major Pharmaceuticals
- 0904-7262- OXCARBAZEPINE
  - 0904-7262-61- 100 BLISTER PACK in 1 CARTON (0904-7262-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7263- OXCARBAZEPINE
  - 0904-7263-61- 100 BLISTER PACK in 1 CARTON (0904-7263-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7264- OXCARBAZEPINE
  - 0904-7264-61- 100 BLISTER PACK in 1 CARTON (0904-7264-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK

10135- Marlex Pharmaceuticals, Inc
- 10135-798- Oxcarbazepine
  - 10135-798-41- 250 mL in 1 BOTTLE, GLASS (10135-798-41)

17772- Supernus Pharmaceuticals, Inc.
- 17772-121- OXTELLAR XR
  - 17772-121-01- 100 TABLET in 1 BOTTLE (17772-121-01)

17772- Supernus Pharmaceuticals, Inc.
- 17772-121- OXTELLAR XR
  - 17772-121-07- 7 TABLET in 1 BOTTLE (17772-121-07)

17772- Supernus Pharmaceuticals, Inc.
- 17772-121- OXTELLAR XR
  - 17772-121-10- 5 TABLET in 1 BLISTER PACK (17772-121-10)

17772- Supernus Pharmaceuticals, Inc.
- 17772-122- OXTELLAR XR
  - 17772-122-01- 100 TABLET in 1 BOTTLE (17772-122-01)

17772- Supernus Pharmaceuticals, Inc.
- 17772-122- OXTELLAR XR
  - 17772-122-07- 7 TABLET in 1 BOTTLE (17772-122-07)

17772- Supernus Pharmaceuticals, Inc.
- 17772-122- OXTELLAR XR
  - 17772-122-10- 5 TABLET in 1 BLISTER PACK (17772-122-10)

17772- Supernus Pharmaceuticals, Inc.
- 17772-123- OXTELLAR XR
  - 17772-123-01- 100 TABLET in 1 BOTTLE (17772-123-01)

17772- Supernus Pharmaceuticals, Inc.
- 17772-123- OXTELLAR XR
  - 17772-123-07- 7 TABLET in 1 BOTTLE (17772-123-07)

17772- Supernus Pharmaceuticals, Inc.
- 17772-123- OXTELLAR XR
  - 17772-123-10- 5 TABLET in 1 BLISTER PACK (17772-123-10)

27241- Ajanta Pharma USA Inc.
- 27241-237- Oxcarbazepine
  - 27241-237-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-237-01)

27241- Ajanta Pharma USA Inc.
- 27241-238- Oxcarbazepine
  - 27241-238-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-238-01)

27241- Ajanta Pharma USA Inc.
- 27241-239- Oxcarbazepine
  - 27241-239-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-239-01)

27241- Ajanta Pharma USA Inc.
- 27241-304- Oxcarbazepine
  - 27241-304-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-304-01)

27241- Ajanta Pharma USA Inc.
- 27241-305- Oxcarbazepine
  - 27241-305-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-305-01)

27241- Ajanta Pharma USA Inc.
- 27241-306- Oxcarbazepine
  - 27241-306-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-306-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-023- Oxcarbazepine
  - 31722-023-01- 100 TABLET, FILM COATED in 1 BOTTLE (31722-023-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-023- Oxcarbazepine
  - 31722-023-05- 500 TABLET, FILM COATED in 1 BOTTLE (31722-023-05)

31722- Camber Pharmaceuticals, Inc.
- 31722-023- Oxcarbazepine
  - 31722-023-10- 1000 TABLET, FILM COATED in 1 BOTTLE (31722-023-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-023- Oxcarbazepine
  - 31722-023-31- 10 BLISTER PACK in 1 CARTON (31722-023-31) / 10 TABLET, FILM COATED in 1 BLISTER PACK

31722- Camber Pharmaceuticals, Inc.
- 31722-024- Oxcarbazepine
  - 31722-024-01- 100 TABLET, FILM COATED in 1 BOTTLE (31722-024-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-024- Oxcarbazepine
  - 31722-024-05- 500 TABLET, FILM COATED in 1 BOTTLE (31722-024-05)

31722- Camber Pharmaceuticals, Inc.
- 31722-024- Oxcarbazepine
  - 31722-024-10- 1000 TABLET, FILM COATED in 1 BOTTLE (31722-024-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-024- Oxcarbazepine
  - 31722-024-31- 10 BLISTER PACK in 1 CARTON (31722-024-31) / 10 TABLET, FILM COATED in 1 BLISTER PACK

31722- Camber Pharmaceuticals, Inc.
- 31722-025- Oxcarbazepine
  - 31722-025-01- 100 TABLET, FILM COATED in 1 BOTTLE (31722-025-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-025- Oxcarbazepine
  - 31722-025-05- 500 TABLET, FILM COATED in 1 BOTTLE (31722-025-05)

31722- Camber Pharmaceuticals, Inc.
- 31722-025- Oxcarbazepine
  - 31722-025-10- 1000 TABLET, FILM COATED in 1 BOTTLE (31722-025-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-025- Oxcarbazepine
  - 31722-025-31- 10 BLISTER PACK in 1 CARTON (31722-025-31) / 10 TABLET, FILM COATED in 1 BLISTER PACK

31722- Camber Pharmaceuticals, Inc.
- 31722-687- OXCARBAZEPINE
  - 31722-687-25- 1 BOTTLE in 1 CARTON (31722-687-25) / 250 mL in 1 BOTTLE

33342- Macleods Pharmaceuticals Limited
- 33342-259- oxcarbazepine
  - 33342-259-67- 1 BOTTLE in 1 CARTON (33342-259-67) / 250 mL in 1 BOTTLE

42419- CTX Lifesciences Pvt. Ltd.
- 42419-006-
  - 42419-006-01- 25 kg in 1 DRUM (42419-006-01)

42419- CTX Lifesciences Pvt. Ltd.
- 42419-006-
  - 42419-006-02- 25 kg in 1 DRUM (42419-006-02)

42806- EPIC PHARMA, LLC
- 42806-600- Oxcarbazepine
  - 42806-600-22- 1 BOTTLE in 1 CARTON (42806-600-22) / 250 mL in 1 BOTTLE

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0046-
  - 48087-0046-0- 50 kg in 1 DRUM (48087-0046-0)

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0114-
  48087-0114-0- 50 kg in 1 DRUM (48087-0114-0)

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0115-
  48087-0115-0- 50 kg in 1 DRUM (48087-0115-0)

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0118-
  48087-0118-0- 50 kg in 1 DRUM (48087-0118-0)

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0157-
  48087-0157-0- 50 kg in 1 DRUM (48087-0157-0)

48087- F.I.S. FABBRICA ITALIANA SINTETICI S.P.A.
- 48087-0158-
  48087-0158-0- 50 kg in 1 DRUM (48087-0158-0)

50268- AvPAK
- 50268-649- Oxcarbazepine
  50268-649-30- 30 CUP, UNIT-DOSE in 1 TRAY (50268-649-30) / 5 mL in 1 CUP, UNIT-DOSE (50268-649-05)

50268- AvPAK
- 50268-679- Oxcarbazepine
  - 50268-679-15- 50 BLISTER PACK in 1 BOX (50268-679-15) / 1 TABLET, FILM COATED in 1 BLISTER PACK (50268-679-11)

50268- AvPAK
- 50268-680- Oxcarbazepine
  - 50268-680-15- 50 BLISTER PACK in 1 BOX (50268-680-15) / 1 TABLET, FILM COATED in 1 BLISTER PACK (50268-680-11)

50268- AvPAK
- 50268-681- Oxcarbazepine
  - 50268-681-15- 50 BLISTER PACK in 1 BOX (50268-681-15) / 1 TABLET, FILM COATED in 1 BLISTER PACK (50268-681-11)

50742- Ingenus Pharmaceuticals, LLC
- 50742-611- Oxcarbazepine
  - 50742-611-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50742-611-01)

50742- Ingenus Pharmaceuticals, LLC
- 50742-612- Oxcarbazepine
  - 50742-612-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50742-612-01)

50742- Ingenus Pharmaceuticals, LLC
- 50742-613- Oxcarbazepine
  - 50742-613-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50742-613-01)

51508- Hubei Gedian Humanwell Pharmaceutical Co.,Ltd
- 51508-008-
  - 51508-008-10- 10 kg in 1 CONTAINER (51508-008-10)

51508- Hubei Gedian Humanwell Pharmaceutical Co.,Ltd
- 51508-008-
  51508-008-20- 20 kg in 1 CONTAINER (51508-008-20)

51508- Hubei Gedian Humanwell Pharmaceutical Co.,Ltd
- 51508-008-
  51508-008-25- 25 kg in 1 CONTAINER (51508-008-25)

51508- Hubei Gedian humanwell Pharmaceutical Co., Ltd
- 51508-205-
  51508-205-01- 1 kg in 1 CONTAINER, FLEXIBLE INTERMEDIATE BULK (51508-205-01)

51508- Hubei Gedian humanwell Pharmaceutical Co., Ltd
- 51508-205-
  51508-205-25- 25 kg in 1 CONTAINER, FLEXIBLE INTERMEDIATE BULK (51508-205-25)

51672- Sun Pharmaceutical Industries, Inc.
- 51672-1393- OXCARBAZEPINE
  51672-1393-1- 1 BOTTLE, GLASS in 1 CARTON (51672-1393-1) / 250 mL in 1 BOTTLE, GLASS

51991- Breckenridge Pharmaceutical, Inc.
- 51991-053- OXCARBAZEPINE
  - 51991-053-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-053-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-053- OXCARBAZEPINE
  - 51991-053-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-053-05)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-054- OXCARBAZEPINE
  - 51991-054-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-054-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-054- OXCARBAZEPINE
  - 51991-054-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-054-05)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-055- OXCARBAZEPINE
  - 51991-055-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-055-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-055- OXCARBAZEPINE
  - 51991-055-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-055-05)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-292- OXCARBAZEPINE
  - 51991-292-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-292-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-292- OXCARBAZEPINE
  - 51991-292-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-292-05)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-293- OXCARBAZEPINE
  - 51991-293-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-293-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-293- OXCARBAZEPINE
  - 51991-293-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-293-05)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-294- OXCARBAZEPINE
  - 51991-294-01- 100 TABLET, FILM COATED in 1 BOTTLE (51991-294-01)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-294- OXCARBAZEPINE
  - 51991-294-05- 500 TABLET, FILM COATED in 1 BOTTLE (51991-294-05)

55154- Cardinal Health 107, LLC
- 55154-2138- Oxcarbazepine
  - 55154-2138-0- 10 BLISTER PACK in 1 BAG (55154-2138-0) / 1 TABLET, FILM COATED in 1 BLISTER PACK

55154- Cardinal Health 107, LLC
- 55154-2139- Oxcarbazepine
  - 55154-2139-0- 10 BLISTER PACK in 1 BAG (55154-2139-0) / 1 TABLET, FILM COATED in 1 BLISTER PACK

55154- Cardinal Health 107, LLC
- 55154-4320- OXCARBAZEPINE
  - 55154-4320-0- 10 BLISTER PACK in 1 BAG (55154-4320-0) / 1 TABLET, FILM COATED in 1 BLISTER PACK

55154- Cardinal Health 107, LLC
- 55154-4323- OXCARBAZEPINE
  - 55154-4323-0- 10 BLISTER PACK in 1 BAG (55154-4323-0) / 1 TABLET, FILM COATED in 1 BLISTER PACK

55512- Archimica S.p.A.
- 55512-0006-
  - 55512-0006-0- 25 kg in 1 DRUM (55512-0006-0)

55512- Archimica S.p.A.
- 55512-0007-
  55512-0007-0- 25 kg in 1 DRUM (55512-0007-0)

55512- Archimica S.p.A.
- 55512-0008-
  55512-0008-0- 50 kg in 1 DRUM (55512-0008-0)

55512- Archimica S.p.A.
- 55512-0016-
  55512-0016-0- 1 kg in 1 BOTTLE (55512-0016-0)

55512- Archimica S.p.A.
- 55512-0017-
  55512-0017-0- 1 kg in 1 BOTTLE (55512-0017-0)

55512- Archimica S.p.A.
- 55512-0018-
  55512-0018-0- 1 kg in 1 BOTTLE (55512-0018-0)

55512- Archimica S.p.A.
- 55512-0023-
  55512-0023-0- 25 kg in 1 DRUM (55512-0023-0)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-088-
  58159-088-01- 35 kg in 1 DRUM (58159-088-01)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-088-
  58159-088-02- 20 kg in 1 DRUM (58159-088-02)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-088-
  58159-088-03- 15 kg in 1 DRUM (58159-088-03)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-088-
  58159-088-04- 10 kg in 1 DRUM (58159-088-04)

58159- NURAY CHEMICALS PRIVATE LIMITED
- 58159-088-
  58159-088-05- 5 kg in 1 DRUM (58159-088-05)

60429- Golden State Medical Supply, Inc.
- 60429-061- OXCARBAZEPINE
  60429-061-01- 100 TABLET, FILM COATED in 1 BOTTLE (60429-061-01)

60429- Golden State Medical Supply, Inc.
- 60429-061- OXCARBAZEPINE
  - 60429-061-05- 500 TABLET, FILM COATED in 1 BOTTLE (60429-061-05)

60429- Golden State Medical Supply, Inc.
- 60429-062- OXCARBAZEPINE
  - 60429-062-01- 100 TABLET, FILM COATED in 1 BOTTLE (60429-062-01)

60429- Golden State Medical Supply, Inc.
- 60429-062- OXCARBAZEPINE
  - 60429-062-05- 500 TABLET, FILM COATED in 1 BOTTLE (60429-062-05)

60429- Golden State Medical Supply, Inc.
- 60429-063- OXCARBAZEPINE
  - 60429-063-01- 100 TABLET, FILM COATED in 1 BOTTLE (60429-063-01)

60429- Golden State Medical Supply, Inc.
- 60429-063- OXCARBAZEPINE
  - 60429-063-05- 500 TABLET, FILM COATED in 1 BOTTLE (60429-063-05)

60505- Apotex Corp.
- 60505-4128- OXCARBAZEPINE
  - 60505-4128-5- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-4128-5)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆